Type 2 diabetes articles for people who want clear, practical guidance on symptoms, diagnosis, blood sugar targets, medicines, food, activity, and long-term risk reduction.Start here for plain-language explainers, safety notes, and care-team questions. Use this information to prepare for conversations with a clinician, not to change prescribed treatment on your own.
A safety update describes a rare eye disorder reported with GLP-1 medicines. Here is what people with diabetes should know about symptoms, uncertainty and urgent care.
BMI remains useful, but new obesity frameworks encourage clinicians to also consider waist-based measurements, health complications, and daily function when assessing people with diabetes.
Recent case reports have raised a rare but serious safety question involving semaglutide, poor intake, rapid weight loss, thiamine deficiency, and neurological symptoms. The evidence shows an association, not proven causation.
The FDA approved monthly Tryngolza for adults with severe hypertriglyceridemia. Here is what people with diabetes should know about its purpose, pancreatitis risk and safety.
A pediatric review found GLP-1 medicines may help selected children and teens with obesity or type 2 diabetes, but long-term safety data remain limited.
An ENDO 2026 real-world study linked semaglutide with fewer bone fractures than several other weight-loss medicines in adults with type 2 diabetes. The finding is interesting, but it does not prove semaglutide prevents fractures.
